問卷

TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Infectious Disease

Division of Pediatrics

更新時間:2023-09-19

夏紹軒
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

14Cases

2023-01-23 - 2025-12-24

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-04-01 - 2028-08-03

Phase II

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
5Sites

Recruiting5Sites

2024-04-01 - 2025-04-30

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2019-08-22 - 2021-06-16

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2023-10-31 - 2025-06-12

Phase II

Completed
A multicenter, single-arm, open-label study to assess the pharmacokinetics, safety, and tolerability of cefiderocol in hospitalized pediatric patients from birth to < 3 months of age with suspected or confirmed aerobic Gram-negative bacterial infections
  • Condition/Disease

    Gram-Negative Bacterial Infections

  • Test Drug

    Cefiderocol

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2021-04-09 - 2024-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2017-09-01 - 2022-12-20

Phase III

A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)
  • Condition/Disease

    Atypical Hemolytic Uremic Syndrome (aHUS)

  • Test Drug

    ALXN1210

Participate Sites
3Sites

Terminated3Sites

1 2